奥扎格雷钠联合低分子肝素钙治疗脑血栓患者临床观察

Effects of ozagrel combined with low molecular heparin calcium on patients with cerebral thrombosis

目的探究奥扎格雷钠联合低分子肝素钙对脑血栓患者神经功能、不良反应及预后的影响。方法选取2015-01—2017-01驻马店市中心医院接受治疗的60例脑血栓患者,并给予随机分组,对照组30例,给予单纯低分子肝素钙治疗;观察组30例,在对照组基础上加用奥扎格雷钠治疗,对2组患者治疗前后的神经功能缺损评分、不良反应发生情况及预后进行综合评价。结果治疗后和对照组相比,观察组患者的神经功能缺损评分显著降低(P<0.05),但治疗前2组患者神经功能缺损评分之间差异无统计学意义(P>0.05)。观察组患者治疗总有效率90.0%(27例)显著高于对照组73.3%(22例)(P<0.05)。治疗后和对照组相比,观察组患者的FIB水平显著降低(P<0.05),但治疗前2组患者的FIB水平之间差异无统计学意义(P>0.05)。治疗前后观察组与对照组患者PLT、APTT、PT之间差异均无统计学意义(P>0.05)。观察组不良反应发生率6.7%(2例)显著低于对照组30.0%(9例)(P<0.05)。观察组复发率3.3%(1例)显著低于对照组23.3%(7例)(P<0.05)。结论联合应用奥扎格雷钠与低分子肝素钙有利于脑血栓患者神经功能的改善,不良反应少。

Objective To investigate the effects of ozagrel combined with low molecular weight heparin calcium on neurological function,adverse reactions and prognosis of patients with cerebral thrombosis.Methods 60 cases of patients with cerebral thrombosis treated in our hospital from February 2015 to February 2017 were retrospectively analyzed.They were randomly divided into control group(30 cases)treated with low molecular weight heparin calcium(LMWH);observation group(30 cases)treated with ozagrel on the basis of control group.The defect scores,incidences of adverse reactions and prognosis were comprehensively evaluated.Results Compared with the control group,the neurological deficit score of the observation group was significantly lower(P<0.05),but the difference before treatment between the two groups was no significant(P>0.05).The total effective rate of the observation group 90.0%(27)was significantly higher than the control group 73.3%(22/30)(P<0.05).After treatment,the FIB level of the observation group was significantly lower than the control group(P<0.05),but the difference before treatment between the two groups was no significant(P>0.05).The differences of PLT,APTT and PT before and after treatment between the observation group and the control group were not significant(P>0.05).The incidence of adverse reactions of the observation group 6.7%(2/30)was significantly lower than the control group 30.0%(9)(P<0.05).The recurrence rate of the observation group 3.3%(1)was significantly lower than the control group 23.3%(7/30)(P<0.05).Conclusion Ozagrel combined with low molecular weight heparin calcium in the treatment of cerebral thrombosis is conducive to the improvement of neurological function of patients with fewer adverse reactions,so is worthy of promotion and application.